Podcasts

OncLive On Air^® is a podcast from OncLive^® that provides oncology professionals with the resources and information they need to provide the best patient care. Segments cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. New episodes with exclusive interviews with leading oncology experts are released on Mondays and Thursdays.

FDA Approval Insights: Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF V600+ Advanced Melanoma

September 17th 2020

In our exclusive interview, Omid Hamid, MD, contextualizes the FDA approval of atezolizumab in combination with cobimetinib and vemurafenib in BRAF V600 mutation–positive advanced melanoma and discusses important takeaways from the IMspire150 trial.

Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate Cancer

September 14th 2020

In our exclusive interview, Dr. Giri and Dr. Gomella discuss the rationale to create the first multidisciplinary, consensus-driven framework for prostate cancer genetic testing, the importance of having a multidisciplinary team weigh in on the recommendations, and key aspects of the guidelines that could have clinical implications for men in this space.

Tolaney Talks Tailored Treatment Strategies in HER2+ Breast Cancer

September 10th 2020

In our exclusive interview, Sara M. Tolaney, MD, MPH, shares insight on how risk status is being used to tailor HER2-directed therapies to patients with early-stage HER2-positive breast cancer, key trials focused on delineating optimal deescalated and escalated treatment strategies, and ongoing research in the HER2-low setting.

Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer

September 7th 2020

In our exclusive interview, Thomas Herzog, MD, and Kathleen Moore, MD, reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.

Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer

September 3rd 2020

In our exclusive interview, Robert L. Coleman, MD, FACOG, FACS and Brian M. Slomovitz, MD, discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.

GU Experts Review Treatment Options, Remaining Challenges, and Future Research in Penile Cancer

August 31st 2020

Today, we had the pleasure of sitting down with a group of experts in genitourinary cancers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Moffitt Cancer Center to discuss a malignancy that is not often an everyday focus: penile cancer.

FDA Approval Insights: Avelumab in Metastatic Urothelial Carcinoma

August 27th 2020

In our exclusive interview, Shilpa Gupta, MD, of Cleveland Clinic, discusses the FDA approval of avelumab in metastatic urothelial carcinoma and key findings from the JAVELIN Bladder 100 study.

Talking Tumors: Evaluating Early-Stage Breast Cancer Cases in the COVID-19 Era

August 24th 2020

In our exclusive interview, Dr. Meisel and Dr. Hamilton provided insight on key data from the 2020 ASCO Virtual Scientific Program and best practices in managing patients during the coronavirus disease 2019 pandemic.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

August 20th 2020

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.

Pegram Unpacks Pivotal Data in Breast Cancer

August 17th 2020

In our exclusive interview, Dr. Pegram discusses the unique structure of trastuzumab deruxtecan, initial and subset analyses from the DESTINY-Breast01 trial, potential adverse effects, and recommended management strategies for the agent.

Research Reflections: Braunstein Breaks Down Top ASCO 2020 Abstracts in Myeloma

August 13th 2020

In our exclusive interview, Marc J. Braunstein, MD, PhD, provides perspective on data in the upfront and relapsed/refractory settings regarding the use of triplet and quadruplet regimens, novel agents, and cellular therapies.

Markman and Monk Provide Perspective on the Utility of PARP Inhibitors in Ovarian Cancer

August 10th 2020

In our exclusive interview, Bradley J. Monk, MD, FACS, FACOG, and Maurie Markman, MD, discuss the rationale behind maintenance therapy, pivotal PARP inhibitor trials in the frontline setting, and the importance of shared-decision making.

Dizon Discusses Elements of Sexual Health in Gynecologic Cancer

August 6th 2020

In our exclusive interview, Don S. Dizon, MD, FACP, FASCO, discusses the primary physical and residual psychological effects of gynecologic cancers on women’s sexual health, the challenges of broaching these topics in the clinic, and the role oncologists play in helping patients manage these difficulties.

FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory MCL

August 3rd 2020

In our exclusive interview, Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

DiNardo Discusses VIALE-A and Venetoclax Combo in AML

July 30th 2020

In our exclusive interview, Courtney DiNardo, MD, MSCE, discusses the role of venetoclax in acute myeloid leukemia and explains the significance of the results of the VIALE-A trial.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess

July 27th 2020

In our exclusive interview, Jonathan W. Riess, MD, MS, discusses the excitement surrounding KRAS G12C inhibitors in non–small cell lung cancer, preliminary efficacy and safety data with AMG 510, and additional research regarding co-mutations and combinations that could lead to further refinement of the potential role of the agent in the landscape.

Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC

July 23rd 2020

In our exclusive interview, Dr. Aggarwal, Dr. Sequist, and Dr. Pennell provided perspective on the results of the ADAURA trial and addressed the potential clinical and financial concerns of using osimertinib in the adjuvant setting in patients with EGFR-mutant NSCLC.

FDA Approval Insights: Selpercatinib in RET+ NSCLC and Thyroid Cancers

July 20th 2020

In our exclusive interview, Alexander Drilon, MD provided background on use of targeted therapy in advanced non–small cell lung cancer, discussed the frequency of RET alterations, and expanded on the data from the LIBRETTO-001 trial that led to the accelerated approval of selpercatinib.

Research Reflections: Sarcoma Experts Consider Emerging Evidence for Novel Combos

July 16th 2020

In our exclusive interview, Shiraj Sen, MD, PhD, and Roman Groisberg, MD, discuss key takeaways from the 2020 ASCO Virtual Scientific Program on exciting efforts being made in the field of sarcoma.

First of its Kind MMRF CureCloud Makes Way for Precision Medicine in Myeloma

July 13th 2020

In our exclusive interview, Dr. Cho and Dr. Ghobrial discuss the inspiration for the MMRF CureCloud, how it advances precision medicine, and the long-term goals of the study for patients and physicians alike.